piracetam has been researched along with HbS Disease in 24 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 8.93 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, A; Fedorowicz, Z, 2016) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 8.84 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, AA; Fedorowicz, Z; Omran, A; Tadmouri, GO, 2007) |
| " Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation." | 7.66 | Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam. ( Burek, L; Collier, BD; Diglio, CA; Fleischman, JA; Henry, RL; Nalbandian, RM; O'Donnell, FE; Reeser, FH; Williams, G, 1982) |
| "Piracetam is a nootropic drug that has reportedly been effective and non-toxic in sickle cell patients, but most studies were not placebo-controlled and included a small number of patients." | 6.71 | Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. ( Alvim, RC; Brito, AC; Franklin, HM; Oliveira, TF; Paula, MJ; Pires, MA; Rezende, PV; Viana, MB, 2005) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 4.93 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, A; Fedorowicz, Z, 2016) |
| "To assess the effectiveness of piracetam for reducing the incidence of painful sickle cell disease crises." | 4.84 | Piracetam for reducing the incidence of painful sickle cell disease crises. ( Al Hajeri, AA; Fedorowicz, Z; Omran, A; Tadmouri, GO, 2007) |
| " Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation." | 3.66 | Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam. ( Burek, L; Collier, BD; Diglio, CA; Fleischman, JA; Henry, RL; Nalbandian, RM; O'Donnell, FE; Reeser, FH; Williams, G, 1982) |
| "Piracetam is a nootropic drug that has reportedly been effective and non-toxic in sickle cell patients, but most studies were not placebo-controlled and included a small number of patients." | 2.71 | Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. ( Alvim, RC; Brito, AC; Franklin, HM; Oliveira, TF; Paula, MJ; Pires, MA; Rezende, PV; Viana, MB, 2005) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | 2.58 | Drugs for preventing red blood cell dehydration in people with sickle cell disease. ( Ballas, SK; Nagalla, S, 2018) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | 2.53 | Drugs for preventing red blood cell dehydration in people with sickle cell disease. ( Ballas, SK; Nagalla, S, 2016) |
| "Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells." | 2.48 | Drugs for preventing red blood cell dehydration in people with sickle cell disease. ( Ballas, SK; Nagalla, S, 2012) |
| "Sickle cell disease is an inherited disorder of haemoglobin, which results in abnormal red blood cells." | 2.44 | Drugs for preventing red blood cell dehydration in people with sickle cell disease. ( Ballas, SK; Singh, PC, 2007) |
| "Sickle cell disease is an inherited disorder of haemoglobin, which results in abnormal red blood cells." | 2.41 | Drugs for preventing red blood cell dehydration in people with sickle cell disease. ( De Franceschi, L; Riddington, C, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (54.17) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagalla, S | 3 |
| Ballas, SK | 4 |
| Al Hajeri, A | 1 |
| Fedorowicz, Z | 2 |
| Viana, MB | 2 |
| Alvim, RC | 2 |
| Riddington, C | 1 |
| De Franceschi, L | 1 |
| Pires, MA | 1 |
| Franklin, HM | 1 |
| Paula, MJ | 1 |
| Brito, AC | 1 |
| Oliveira, TF | 1 |
| Rezende, PV | 1 |
| Winblad, B | 1 |
| Al Hajeri, AA | 1 |
| Omran, A | 1 |
| Tadmouri, GO | 1 |
| Singh, PC | 1 |
| Franklin, IM | 1 |
| Aluoch, JR | 1 |
| Nalbandian, RM | 3 |
| Henry, RL | 3 |
| Burek, CL | 1 |
| Diglio, CA | 2 |
| Goldman, AI | 1 |
| Taylor, GW | 1 |
| Hoffman, WH | 1 |
| Fleischman, JA | 1 |
| Burek, L | 1 |
| Williams, G | 1 |
| O'Donnell, FE | 1 |
| Collier, BD | 1 |
| Reeser, FH | 1 |
| Asakura, T | 1 |
| Ohnishi, ST | 1 |
| Adachi, K | 1 |
| Ozguc, M | 1 |
| Hashimoto, K | 1 |
| Devlin, MT | 1 |
| Schwartz, E | 1 |
| el-Hazmi, MA | 1 |
| Warsy, AS | 1 |
| al-Fawaz, I | 1 |
| Opawoye, AO | 1 |
| Taleb, HA | 1 |
| Howsawi, Z | 1 |
| Mohamed, AA | 1 |
| Aly, AW | 1 |
| Refai, S | 1 |
| Sugathan, PS | 1 |
| Rab, AS | 1 |
| Ahmed, HB | 1 |
| Abulaban, M | 1 |
| Abdulkader, AM | 1 |
| Farid, M | 1 |
| de Melo, GO | 1 |
| de Araujo, JT | 1 |
| Nero, GS | 1 |
| Murayama, M | 1 |
| Costa, FF | 1 |
| Zago, MA | 1 |
| Bottura, C | 1 |
| Salzano, FM | 1 |
| Guardigni, L | 1 |
| Salvi, P | 1 |
| Passini, S | 1 |
| Stagno, S | 1 |
| Pretolani, E | 1 |
| Gini, EK | 2 |
| Sonnet, J | 2 |
| Cornu, G | 1 |
9 reviews available for piracetam and HbS Disease
| Article | Year |
|---|---|
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical T | 2018 |
Piracetam for reducing the incidence of painful sickle cell disease crises.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Pain; Piracet | 2016 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical T | 2016 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase II as Topic; Clinical T | 2012 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Dehydration; Erythrocytes; Humans; Piracetam; Randomized C | 2002 |
Piracetam: a review of pharmacological properties and clinical uses.
Topics: Anemia, Sickle Cell; Animals; Cerebrovascular Circulation; Cognition Disorders; Drug Evaluation; Dys | 2005 |
Piracetam for reducing the incidence of painful sickle cell disease crises.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Pain; Piracet | 2007 |
Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Dehydration; Erythrocytes; Humans; Piracetam; Randomized C | 2007 |
The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azepines; Clinical Trials as Topic; Cyanates; Deamino Argi | 1984 |
4 trials available for piracetam and HbS Disease
| Article | Year |
|---|---|
Painful crises in children with sickle cell disease are not prevented by piracetam.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Double-Blind Method; Female; Humans | 2009 |
Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Cross-Over Studies; Double-Blind Me | 2005 |
The treatment of sickle cell disease. A historical and chronological literature review of the therapies applied since 1910.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azepines; Clinical Trials as Topic; Cyanates; Deamino Argi | 1984 |
Piracetam is useful in the treatment of children with sickle cell disease.
Topics: Anemia, Sickle Cell; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Hospit | 1996 |
12 other studies available for piracetam and HbS Disease
| Article | Year |
|---|---|
Piracetam and sickle-cell disease.
Topics: Anemia, Sickle Cell; Erythrocytes, Abnormal; Humans; Piracetam; Pyrrolidinones | 1980 |
Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam.
Topics: Anemia, Sickle Cell; Animals; Cell Adhesion; Cells, Cultured; Endothelium; Erythrocytes, Abnormal; H | 1983 |
Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam.
Topics: Anemia, Sickle Cell; Cell Adhesion; Diabetes Mellitus; Endothelium; Erythrocytes; Humans; Malaria; P | 1982 |
Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
Topics: Anemia, Sickle Cell; Blood Viscosity; Erythrocytes, Abnormal; Gels; Hemoglobin, Sickle; Humans; In V | 1981 |
Piracetam in sickle-cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Drug Evaluation; Humans; Piracetam; Pyrrol | 1976 |
Piracetam and acetamide in sickle-cell disease.
Topics: Acetamides; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dr | 1977 |
Sickle-cell disease: Two new therapeutic strategies.
Topics: Anemia, Sickle Cell; Antisickling Agents; Drug Evaluation; Erythrocyte Membrane; Humans; Molecular C | 1978 |
Effects of piracetam and iodoacetamide on erythrocyte sickling.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Erythrocyte Aging; Erythrocytes, Abnormal; Humans | 1979 |
Incidence, effects, and management of sickle cell disease in Brazil.
Topics: Anemia, Sickle Cell; Brazil; Female; Fetal Hemoglobin; Genetic Carrier Screening; Genetic Counseling | 1985 |
[A clinical case. Sickle cell crisis in drepanocytic anemia].
Topics: Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blood Transfusion; Female; Huma | 1988 |
Use of piracetam improves sickle cell deformability in vitro and in vivo.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Erythrocyte Deformability; Female; | 1987 |
[Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam].
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Child; Child, Preschool; Drug Evaluation; Hum | 1985 |